Electromed Inc. logo

Electromed Inc. (ELMD)

Market Closed
1 Sep, 20:00
AMEX AMEX
$
27. 10
-0.87
-3.1105%
$
245.09M Market Cap
32 P/E Ratio
- Div Yield
167,953 Volume
0.47 Eps
$ 27.97
Previous Close
Add Transaction
Day Range
26.89 29.9
Year Range
23.01 47.4
Want to track ELMD and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript

Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript

Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript

Seekingalpha | 6 days ago
Electromed, Inc. (ELMD) Surpasses Q4 Earnings Estimates

Electromed, Inc. (ELMD) Surpasses Q4 Earnings Estimates

Electromed, Inc. (ELMD) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share a year ago.

Zacks | 6 days ago
Electromed (ELMD) Is a Great Choice for 'Trend' Investors, Here's Why

Electromed (ELMD) Is a Great Choice for 'Trend' Investors, Here's Why

Electromed (ELMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks | 1 month ago
Here's Why Momentum in Electromed (ELMD) Should Keep going

Here's Why Momentum in Electromed (ELMD) Should Keep going

If you are looking for stocks that are well positioned to maintain their recent uptrend, Electromed (ELMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks | 2 months ago
Electromed: Strong Margins, Strong Growth, Large Runway

Electromed: Strong Margins, Strong Growth, Large Runway

Electromed is rated 'buy' due to accelerating growth, margin expansion, and a large underpenetrated bronchiectasis market. ELMD benefits from a new CMS rule and a recently approved bronchiectasis drug, both driving increased disease awareness and streamlined clinician adoption. Gross margin improved to 78.5%, operating margin rose to 20.4%, and net income reached a record $3.0 million in Q3 FY 2026.

Seekingalpha | 2 months ago
Is Electromed (ELMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

Is Electromed (ELMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

Electromed (ELMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks | 3 months ago
Best Momentum Stocks to Buy for June 2nd

Best Momentum Stocks to Buy for June 2nd

GOLD, ELMD and TPR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 2nd, 2026.

Zacks | 3 months ago
Electromed, Inc. (ELMD) Hits Fresh High: Is There Still Room to Run?

Electromed, Inc. (ELMD) Hits Fresh High: Is There Still Room to Run?

Electromed (ELMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks | 3 months ago
3 Medical Instrument Stocks Exploring GenAI to Tackle Industry Woes

3 Medical Instrument Stocks Exploring GenAI to Tackle Industry Woes

GenAI is reshaping medical instruments as Electromed, Globus Medical and Intuitive Surgical navigate M&A and market pressures.

Zacks | 3 months ago
Electromed, Inc. (ELMD)'s Technical Outlook is Bright After Key Golden Cross

Electromed, Inc. (ELMD)'s Technical Outlook is Bright After Key Golden Cross

Electromed, Inc. (ELMD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ELMD's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.

Zacks | 3 months ago
Electromed (ELMD) is an Incredible Growth Stock: 3 Reasons Why

Electromed (ELMD) is an Incredible Growth Stock: 3 Reasons Why

Electromed (ELMD) possesses solid growth attributes, which could help it handily outperform the market.

Zacks | 3 months ago
What Makes Electromed (ELMD) a Good Fit for 'Trend Investing'

What Makes Electromed (ELMD) a Good Fit for 'Trend Investing'

Electromed (ELMD) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks | 3 months ago
Loading...
Load More